These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 37901250)

  • 1. The tumor micro-environment in pediatric glioma: friend or foe?
    Messiaen J; Jacobs SA; De Smet F
    Front Immunol; 2023; 14():1227126. PubMed ID: 37901250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune Infiltrating Cells-Derived Risk Signature Based on Large-scale Analysis Defines Immune Landscape and Predicts Immunotherapy Responses in Glioma Tumor Microenvironment.
    Zhang N; Zhang H; Wang Z; Dai Z; Zhang X; Cheng Q; Liu Z
    Front Immunol; 2021; 12():691811. PubMed ID: 34489938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circadian Regulation Patterns With Distinct Immune Landscapes in Gliomas Aid in the Development of a Risk Model to Predict Prognosis and Therapeutic Response.
    Tian R; Li Y; Shu M
    Front Immunol; 2021; 12():797450. PubMed ID: 35069579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in research on immune escape mechanism of glioma.
    Guo X; Wang G
    CNS Neurosci Ther; 2023 Jul; 29(7):1709-1720. PubMed ID: 37088950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deciphering diffuse glioma immune microenvironment as a key to improving immunotherapy results.
    Picca A; Finocchiaro G
    Curr Opin Oncol; 2022 Nov; 34(6):653-660. PubMed ID: 36000367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PLEKHA4 is a novel prognostic biomarker that reshapes the tumor microenvironment in lower-grade glioma.
    Zhi W; Wang Y; Jiang C; Gong Y; Chen Q; Mao X; Deng W; Zhao S
    Front Immunol; 2023; 14():1128244. PubMed ID: 37818357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The intrinsic and microenvironmental features of diffuse midline glioma: Implications for the development of effective immunotherapeutic treatment strategies.
    Persson ML; Douglas AM; Alvaro F; Faridi P; Larsen MR; Alonso MM; Vitanza NA; Dun MD
    Neuro Oncol; 2022 Sep; 24(9):1408-1422. PubMed ID: 35481923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and validation of a personalized classifier to predict the prognosis and response to immunotherapy in glioma based on glycolysis and the tumor microenvironment.
    Fan P; Xia J; Zhou M; Zhuo C; He H
    PeerJ; 2023; 11():e16066. PubMed ID: 37744243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The combined signatures of telomere and immune cell landscape provide a prognostic and therapeutic biomarker in glioma.
    Han X; Yan Z; Fan K; Guan X; Hu B; Li X; Ou Y; Cui B; An L; Zhang Y; Gong J
    Front Immunol; 2023; 14():1220100. PubMed ID: 37662954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Role of Myeloid Cells in GBM Immunosuppression.
    Lin YJ; Wu CY; Wu JY; Lim M
    Front Immunol; 2022; 13():887781. PubMed ID: 35711434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pediatric brain tumors: the era of molecular diagnostics, targeted and immune-based therapeutics, and a focus on long term neurologic sequelae.
    Plant-Fox AS; O'Halloran K; Goldman S
    Curr Probl Cancer; 2021 Aug; 45(4):100777. PubMed ID: 34303558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of Novel m6A Regulator-mediated Methylation Modification Patterns in Distinct Tumor Microenvironment Profiles to Identify and Predict Glioma Prognosis and Progression, T-cell Dysfunction, and Clinical Response to ICI Immunotherapy.
    Zhao B; Xiang Z; Wu B; Zhang X; Feng N; Wei Y; Zhang W
    Curr Pharm Des; 2023; 29(1):60-78. PubMed ID: 36503445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New insights into the Immune TME of adult-type diffuse gliomas.
    Richard Q; Laurenge A; Mallat M; Sanson M; Castro-Vega LJ
    Curr Opin Neurol; 2022 Dec; 35(6):794-802. PubMed ID: 36226710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human Mitochondrial Ribosomal RNA Modification-Based Classification Contributes to Discriminate the Prognosis and Immunotherapy Response of Glioma Patients.
    Wang P; Li J; Wu M; Ye M; Huang K; Zhu X
    Front Immunol; 2021; 12():722479. PubMed ID: 34566979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipid metabolism-related gene signature predicts prognosis and depicts tumor microenvironment immune landscape in gliomas.
    Li J; Zhang S; Chen S; Yuan Y; Zuo M; Li T; Wang Z; Liu Y
    Front Immunol; 2023; 14():1021678. PubMed ID: 36860853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Positive regulators of T cell functions as predictors of prognosis and microenvironment characteristics of low-grade gliomas.
    Li Y; Feng Y; Luo F; Peng G; Li Y
    Front Immunol; 2022; 13():1089792. PubMed ID: 36726969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment Response and Prognosis Evaluation in High-Grade Glioma: An Imaging Review Based on MRI.
    Zhou Q; Xue C; Ke X; Zhou J
    J Magn Reson Imaging; 2022 Aug; 56(2):325-340. PubMed ID: 35129845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of myeloid cells in the immunosuppressive microenvironment in gliomas.
    Locarno CV; Simonelli M; Carenza C; Capucetti A; Stanzani E; Lorenzi E; Persico P; Della Bella S; Passoni L; Mavilio D; Bonecchi R; Locati M; Savino B
    Immunobiology; 2020 Jan; 225(1):151853. PubMed ID: 31703822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-Cell Omics in Dissecting Immune Microenvironment of Malignant Gliomas-Challenges and Perspectives.
    Kaminska B; Ochocka N; Segit P
    Cells; 2021 Aug; 10(9):. PubMed ID: 34571910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glioma-associated microglia/macrophages (GAMs) in glioblastoma: Immune function in the tumor microenvironment and implications for immunotherapy.
    Lin C; Wang N; Xu C
    Front Immunol; 2023; 14():1123853. PubMed ID: 36969167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.